News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeuroVive Pharmaceutical AB Rights Issue 270 Percent Oversubscribed


1/31/2014 9:23:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NeuroVive Pharmaceutical AB (publ) (STO:NVP) has completed the rights issue approved by an Extraordinary General Meeting on 13 December 2013. The subscription period was 13-27 January 2014. The rights issue was fully subscribed, raising approximately SEK 75.8 m for NeuroVive before issue expenses. Additionally, the Board of Directors has decided to fully exercise its overallocation option of a maximum of 714,286 shares, raising a further SEK 10 m for the company.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES